Maridea Wealth Management LLC Acquires New Position in Edwards Lifesciences Corporation $EW

Maridea Wealth Management LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, Holdings Channel reports. The firm bought 22,687 shares of the medical research company’s stock, valued at approximately $2,052,000.

Several other large investors also recently bought and sold shares of EW. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on EW. UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target for the company. Piper Sandler reissued an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $87.00 to $101.00 in a report on Friday, July 24th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Insider Activity

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the sale, the vice president directly owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,190 shares of company stock valued at $2,269,697 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 1.1%

NYSE EW opened at $91.51 on Friday. The company has a market capitalization of $52.69 billion, a PE ratio of 52.59, a P/E/G ratio of 2.30 and a beta of 0.85. The company has a fifty day moving average of $88.73 and a 200 day moving average of $84.37. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.